Market Newsdesk

Washington, D.C., Feb. 23, 2021 (GLOBE NEWSWIRE) — Enveil, the pioneering data security company protecting Data in Use, today announced the release of version 3.0 of its flagship ZeroReveal® product line. ZeroReveal® 3.0 is the most mature encrypted search, analytic, and machine learning solution on the market, delivering the company’s core homomorphic encryption-powered capabilities through an efficient and decentralized framework designed to reduce risk and address business challenges including data sharing, collaboration, monetization, and regulatory compliance. The enhancements in this release achieve dramatic performance improvements — version 3.0 performs at speeds more than 1000x faster than the company’s initial offering released in 2017. Organizations can utilize the groundbreaking, privacy-preserving capabilities at scale to enable critical business functions as part of normal workflows.  

Defining the transformative category of Privacy Enhancing Technologies (PETs), Enveil’s ZeroReveal® solutions change the paradigm of how and where organizations can securely and privately leverage data assets for business purposes — activities that are becoming increasingly challenging due to a growing demand for privacy and a corresponding expansion of the regulatory landscape. The market for these business-enabling capabilities has never been greater: Gartner analysts predict that by 2025, 50% of large organizations will adopt privacy-enhancing computation for processing data in untrusted environments and multiparty data analytics use cases (Gartner “Top Strategic Technology Trends for 2021,” Oct. 2020). Enveil is already delivering on this promise. Customers use ZeroReveal® to securely derive insights, cross-match, and search third-party data assets without ever revealing the content of the search itself or compromising the security or ownership of the underlying data.  

“ZeroReveal 3.0 marks a significant milestone in our company journey and further validates that homomorphic encryption is no longer solely within the realm of research and now has a solid footing in the land of the possible,” said Dr. Ellison Anne Williams, Founder and CEO of Enveil. “Our customers are using ZeroReveal today to uniquely solve real problems at scale, enabling business and mission functions that otherwise just cannot be done. We’re not improving existing processes; we’re making something entirely new possible.”   

By focusing on the security and privacy posture of the search or analytic, Enveil ZeroReveal® protects a customer’s interests and intent as well as the content of the operation and its corresponding results. Information can be securely shared between entities and across jurisdictional boundaries, expanding data access and utility and enabling organizations to reduce risk while making faster, better-informed decisions. The proxy-layer software solution is being used for business-enabling applications in regulated industries such as financial services and healthcare. 

Through its ZeroReveal® solutions, Enveil uniquely provides a decentralized approach to secure data collaboration, allowing participating entities to retain granular control and ownership of their sensitive assets — an approach that differentiates the company’s solution from other Privacy Enhancing Technology-based offerings. Since requirements to move or pool sensitive assets frequently prove to be the breaking point in collaboration efforts, Enveil removes that risk by allowing organizations to securely and privately search and share over third-party data as it is and where it is today. 

“The industry has been waiting not only for homomorphic encryption to reach the computational tipping point, but also for a solution that is built with the needs of business users in mind because both are required for wide-scale use,” said Bob Ackerman, Founder & Managing Director at Allegis Capital. “The performance gains and efficiencies delivered by ZeroReveal 3.0 prove that Enveil has crossed that threshold — and the fact that the company’s approach prioritizes data control and ownership shows that they understand the market in a way that will advance this category.”   

Product Highlights

The product enhancements delivered in the 3.0 release strengthen integration, performance, and user experience features for both Enveil’s ZeroReveal® Search and ZeroReveal® Machine Learning product lines. Notable features include:

• Performance enhancements that deliver substantial processing gains over previous versions: users realize an average 40% performance improvement gain for most use cases — scenarios where encrypted results were already being returned in seconds;
• Enhanced capabilities for robust fuzzy matching;
• Native support for encrypted geospatial queries;
• Support for encrypted queries that return large data files, such as videos or high-resolution images;
• Minimized file sizes for encrypted queries to support edge compute use cases in low-bandwidth environments;
• Utilization of industry-standard APIs to work with existing security and data infrastructure including audit frameworks; and
• Ability to leverage and integrate with a wide range of popular open source homomorphic encryption libraries.

“Our goal is always to deliver products that function at the speed of business, a threshold that we are proudly meeting and exceeding for our existing customer base in both the commercial and federal markets,” said Dr. Ryan Carr, CTO and VP of Engineering at Enveil. “The performance dynamics of 3.0 were aimed at further improving customer experience, and we are now utilizing homomorphic encryption with efficiencies of scale that are beyond even what we imagined to be possible four years ago.”   

About Enveil 

Enveil is a pioneering data security company protecting Data in Use. Enveil’s business-enabling and privacy-preserving capabilities for secure data search, sharing, and collaboration protect data while it’s being used or processed – the ‘holy grail’ of data encryption. Defining the transformative category of Privacy Enhancing Technologies (PETs), Enveil’s homomorphic encryption-powered ZeroReveal® solutions allow organizations to securely derive insights, cross-match, and search third-party data assets without ever revealing the contents of the search itself or compromising the security or ownership of the underlying data. Enveil is a 2020 World Economic Forum Technology Pioneer and its award-winning, market-ready solutions are delivering nation-state level protection to the global marketplace. Founded by U.S. Intelligence Community alumni with backgrounds in mathematics, algorithmics, and machine learning, Enveil is revolutionizing data privacy and security by addressing a Data in Use vulnerability that people have been chasing for more than 30 years. Learn more at www.enveil.com.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, CHICAGO and MONTREAL, Feb. 23, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (Frankfurt: P731) announced today that it has closed its previously announced bought deal public offering of 4,581,689 units (the “Units”) at a price of $7.10 per Unit for total gross proceeds of approximately $32,529,992 (the “Offering”), including 597,611 Units sold pursuant to the exercise in full of the over-allotment option granted to the Underwriters (as defined herein).

The Offering was led by Raymond James Ltd. and Stifel GMP, as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters consisting of Roth Canada, ULC, Bloom Burton Securities Inc. and Mackie Research Capital Corporation (collectively, the “Underwriters”).

Each Unit consists of one common share (each a “Common Share”) and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at a price equal to $10.00 until February 23, 2023. In the event that the volume weighted average trading price of the Common Shares on the TSX Venture Exchange for ten (10) consecutive trading days exceeds $14.00, the Company may, within 10 business days of the occurrence of such event, deliver a notice (including a press release) to the holders of Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice. The Warrants issued pursuant to the Offering have been conditionally approved for listing and are expected to commence trading on the TSX Venture Exchange under the symbol “MDP.WT” shortly following the closing of the Offering, subject to the satisfaction of all listing conditions.

As previously announced, the Company intends to use the net proceeds to fund certain payments owed to medac GmbH under the commercialization and supply agreement (the “Agreement”) dated February 2, 2021 as such payments become due pursuant to the terms of the Agreement and for working capital and general corporate purposes.

The Units were offered and sold by way of a final short form prospectus dated February 17, 2021 (the “Prospectus”) filed in each of the provinces of Canada and offered and sold elsewhere outside of Canada on a private placement basis. Further details of the Offering are set out in the Prospectus, available on the Company’s SEDAR profile at www.sedar.com.

The securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any U.S. state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. persons” (as such term is defined in Regulation S under the 1933 Act) without registration under the U.S. Securities Act and all applicable state securities laws or compliance with the requirements of an applicable exemption therefrom. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities to, for the account or benefit of, persons in the United States or U.S. persons, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Medexus

Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject^®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY^®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall^®, an innovative prescription allergy medication with a unique mode of action.

For more information, please contact:

Ken d’Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.
Tel.: 905-676-0003
E-mail: [email protected]

Roland Boivin, Chief Financial Officer
Medexus Pharmaceuticals Inc.
Tel.: 514-344-8765
E-mail: [email protected]

Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
E-mail: [email protected]

Investor Relations (Canada):
Tina Byers
Adelaide Capital
Tel: 905-330-3275
E-mail: [email protected]

Forward looking and other cautionary statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). The words “anticipates”, “believes”, “expects”, “will”, “plans” and similar expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Specific forward-looking statements contained in this news release include, but are not limited to, statements with respect to the timing of and final approval for the listing of the Warrants on the TSX Venture Exchange and the anticipated use of proceeds of the Offering. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include those set out in the Company’s materials filed with the Canadian securities regulatory authorities from time to time, including the Company’s most recent annual information form and management’s discussion and analysis; future capital requirements and dilution; intellectual property protection and infringement risks; competition (including potential for generic competition); reliance on key management personnel; the Company’s ability to implement its business plan; the Company’s ability to leverage its United States and Canadian infrastructure to promote additional growth, including with respect to the infrastructure of Medexus Inc. and Medac Pharma, Inc. and the potential benefits the Company expects to derive therefrom; regulatory approval by the Canadian health authorities; product reimbursement by third party payers; patent litigation or patent expiry; litigation risk; stock price volatility; government regulation; and potential third party claims. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of the date hereof. Other than as specifically required by law, the Company undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

BURLINGTON, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) — Media technology provider Avid Technology, Inc. (NASDAQ: AVID) today announced the appointment of Adistec^® Corp. as sole master distributor of all Avid^® audio and video products to Avid’s reseller network throughout 17 Latin American countries. Establishing Adistec as a strategic partner, Avid will leverage Adistec’s localized expertise to accelerate its logistics, finance and other processes in the region to keep pace with demand for content creation and management tools and solutions in television, film, music, and education markets.

Headquartered in Miami, Adistec is a value-added distributor of datacenter, networking and security technologies, specializing in the discrete business and technology requirements that vary widely from country to country. Adistec complements its offerings with cloud services running in several proprietary datacenters, as well as extensive consulting and educational services. Many technology companies rely on Adistec to extend their products into Latin America, including several Fortune 1,000 brands in IT and networking. Avid is the inaugural partner for Adistec’s recently created media and entertainment practice.

“Avid and Adistec have begun a deep collaboration through a new distribution relationship that will be extremely important in augmenting Avid’s operations throughout Latin America and making marketing, selling and delivery of all of our products much easier and faster for our resellers,” said Tom Cordiner, Chief Revenue Officer, Avid. Mr. Cordiner continued, “We believe our agreement will better position Avid for overall growth in the region and that Adistec’s additional expertise in driving sales of cloud workflows should help accelerate Avid’s subscription revenues. Additionally, by working directly with Adistec, our ecosystem of existing strategic channel partners will continue to bring substantial value to Avid’s media and entertainment customers throughout Latin America.”

“By matching Adistec’s business and technology capabilities with Avid’s core competencies, we’ll enhance the reach and performance everywhere in Latin America of the most celebrated media technology brand,” said Fabian Sperman, President, Adistec. “Adistec is proud to build our media and entertainment practice around Avid as our cornerstone. We anticipate adding to the success of Avid and its resellers in their core markets while ultimately helping them to expand into new markets for professional video and audio technologies.”

About Adistec  
Adistec has become a leader in value-added distribution for Latin America and the Caribbean. Established in 2002, our organization delivers 100% IT solutions through channels. We are a team of professionals specialized in Datacenter and Security bringing a portfolio of leading brands in each of these areas to our business partners. We strengthen our partners’ business through five business units: Distribution, Education, Professional Services, Cloud Solutions and Adistec Integrated Solutions.

About Avid

Avid delivers the most open and efficient media platform, connecting content creation with collaboration, asset protection, distribution, and consumption. Avid’s preeminent customer community uses Avid’s comprehensive tools and workflow solutions to create, distribute and monetize the most watched, loved and listened to media in the world—from prestigious and award-winning feature films to popular television shows, news programs and televised sporting events, and celebrated music recordings and live concerts. With the most flexible deployment and pricing options, Avid’s industry-leading solutions include Media Composer^®, Pro Tools^®, Avid NEXIS^®, MediaCentral^®, iNEWS^®, AirSpeed^®, Sibelius^®, Avid VENUE^™, FastServe^®, and Maestro^™. For more information about Avid solutions and services, visit www.avid.com, connect with Avid on Facebook, Instagram, Twitter, YouTube, LinkedIn, or subscribe to Avid Blogs.

© 2021 Avid Technology, Inc. All rights reserved. Avid, the Avid logo, Avid NEXIS, FastServe, AirSpeed, iNEWS, Maestro, MediaCentral, Media Composer,
Pro Tools, Avid VENUE, and Sibelius are trademarks or registered trademarks of Avid Technology, Inc. or its subsidiaries in the United States and/or other countries. Adistec is a registered trademark of Adistec Corporation. All other trademarks are the property of their respective owners. Product features, specifications, system requirements and availability are subject to change without notice.

PR Contact:

Avid
Dave Smith
978.502.9607
[email protected]

Developer of World’s First Industrial Centrifugal Partition Chromatography Platform Extends Leadership Team

Budapest, Hungary, Feb. 23, 2021 (GLOBE NEWSWIRE) —

via NewMediaWire — RotaChrom Technologies (“RotaChrom” or the “Company”), the developer of the world’s first industrial-scale Centrifugal Partition Chromatography (CPC) technology platform, announced today the promotion of Andras Gaspar, Ph.D., to Chief Product Officer.

In his new role, Andras will oversee all product development and engineering processes at RotaChrom, where his intimate knowledge of chemistry and engineering required to run the Company’s chromatography product lines will be put to use. The products and services that RotaChrom provides are of the highest quality and at the forefront of purification technology, and Andras will continue to ensure this level of quality for all RotaChrom customers.

“Andras has made tremendous contributions to RotaChrom’s effort to provide the best purification solutions to our customers.” said RotaChrom CEO László Madarász. “We look forward to him taking more of a leadership role within the Company and having him provide his expertise to continue to make RotaChrom the top choice for purification solutions.”

Andras will also continue to be a prominent voice on RotaChrom’s webinar and accompanying “Purified” podcast series, which are monthly discussions around organic compound purification. “Purified” features guest speakers from RotaChrom’s webinar series in order to offer a more personal, conversational-style deep dive into the subjects covered on the webinars.

Andras Gaspar studied bioengineering at the Budapest University of Technology and Economics and went on to earn his Ph.D. in chemistry at the Technical University of Munich. After more than a decade of engineering work at IBV Hungary, Gates Corporation, and Continental ContiTech, Andras joined RotaChrom Technologies in 2020.

For more information about RotaChrom Technologies, visit RotaChrom.com/.

RotaChrom Technologies

RotaChrom Technologies has developed the world’s first industrial-scale Centrifugal Partition Chromatography (pCPC) technology platform with fully automated solvent recycling system. The company’s instruments have revolutionized compound purification by providing cost-effective chromatography solutions to customers all over the world in various industries including pharmaceutical, nutraceutical, food/beverage, and botanical extracts. RotaChrom has achieved massive international success in pharmaceutical purification, and it has become an industry-leading company by setting global purification standards. RotaChrom’s CPC platforms are quintessential applications when looking for a high-purity, high-capacity, and yield-focused solution.

Media Contact:

Stephanie Plieness

CMW Media

858.264.6600

[email protected]